Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma

In elderly patients with newly diagnosed multiple myeloma (MM), the addition of bortezomib to standard, combined oral melphalan and prednisone (MP) significantly increases the response rate and event‐free survival compared with MP alone.

[1]  M. Boccadoro,et al.  Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. , 2010, Blood.

[2]  M. Boccadoro,et al.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Miguel,et al.  Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. , 2010, The Lancet. Oncology.

[4]  D. Esseltine,et al.  Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  P. L. Bergsagel,et al.  Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. , 2010, Blood.

[6]  D. Esseltine,et al.  Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline , 2009, British journal of haematology.

[7]  Bin Jiang,et al.  Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. , 2008, The New England journal of medicine.

[8]  J. Tariman,et al.  Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. , 2008, Clinical journal of oncology nursing.

[9]  J. Berenson,et al.  Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up , 2008, Annals of Hematology.

[10]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[11]  Anthony Boral,et al.  Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. , 2007, Blood.

[12]  P. Sonneveld,et al.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  M. Boccadoro,et al.  Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. , 2007, Blood.

[14]  P. Richardson,et al.  The emerging role of novel therapies for the treatment of relapsed myeloma. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  B. Barlogie,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[16]  R. Pazdur,et al.  United States Food and Drug Administration Approval Summary: Bortezomib for the Treatment of Progressive Multiple Myeloma after One Prior Therapy , 2006, Clinical Cancer Research.

[17]  D. Schenkein,et al.  Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Borad,et al.  The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  J. Crowley,et al.  Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. , 2002, Blood.

[20]  J. Bryant,et al.  Incorporating toxicity considerations into the design of two-stage phase II clinical trials. , 1995, Biometrics.

[21]  H. Wilson,et al.  Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. , 1969, JAMA.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  F. Mandelli,et al.  Continuous Low Dose of Melphalan and Prednisone in Patients with Multiple Myeloma of Very Old Age or Severe Associated Disease , 2002, Drugs & aging.

[24]  D.,et al.  Regression Models and Life-Tables , 2022 .